GH Research (GHRS) Competitors $8.88 +0.28 (+3.26%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends GHRS vs. IRON, WVE, BLTE, ARQT, GLPG, INDV, AKRO, DYN, IMCR, and EVOShould you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Disc Medicine (IRON), Wave Life Sciences (WVE), Belite Bio (BLTE), Arcutis Biotherapeutics (ARQT), Galapagos (GLPG), Indivior (INDV), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), Immunocore (IMCR), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. GH Research vs. Disc Medicine Wave Life Sciences Belite Bio Arcutis Biotherapeutics Galapagos Indivior Akero Therapeutics Dyne Therapeutics Immunocore Evotec Disc Medicine (NASDAQ:IRON) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk, community ranking and earnings. Does the media favor IRON or GHRS? In the previous week, Disc Medicine had 1 more articles in the media than GH Research. MarketBeat recorded 3 mentions for Disc Medicine and 2 mentions for GH Research. GH Research's average media sentiment score of 0.86 beat Disc Medicine's score of -0.36 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral GH Research 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, IRON or GHRS? Disc Medicine has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, GH Research has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Do institutionals & insiders have more ownership in IRON or GHRS? 83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 4.2% of Disc Medicine shares are held by insiders. Comparatively, 41.6% of GH Research shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is IRON or GHRS more profitable? GH Research's return on equity of -20.29% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -25.24% -23.96% GH Research N/A -20.29%-19.49% Which has stronger earnings & valuation, IRON or GHRS? Disc Medicine is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$76.43M-$3.98-14.63GH ResearchN/AN/A-$35.59M-$0.79-11.24 Do analysts rate IRON or GHRS? Disc Medicine presently has a consensus target price of $87.50, indicating a potential upside of 50.24%. GH Research has a consensus target price of $35.67, indicating a potential upside of 301.65%. Given GH Research's higher possible upside, analysts clearly believe GH Research is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10GH Research 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer IRON or GHRS? Disc Medicine received 25 more outperform votes than GH Research when rated by MarketBeat users. Likewise, 84.75% of users gave Disc Medicine an outperform vote while only 73.53% of users gave GH Research an outperform vote. CompanyUnderperformOutperformDisc MedicineOutperform Votes5084.75% Underperform Votes915.25%GH ResearchOutperform Votes2573.53% Underperform Votes926.47% SummaryGH Research beats Disc Medicine on 9 of the 16 factors compared between the two stocks. Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHRS vs. The Competition Export to ExcelMetricGH ResearchPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$462.01M$6.34B$5.21B$8.93BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-11.249.8989.8017.35Price / SalesN/A315.771,248.2377.32Price / CashN/A61.4443.8235.97Price / BookN/A6.055.324.79Net Income-$35.59M$154.90M$122.69M$225.00M7 Day Performance3.62%-1.70%-0.17%1.52%1 Month Performance20.16%1.93%3.49%4.88%1 Year Performance51.79%3.14%25.79%20.12% GH Research Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHRSGH Research1.8753 of 5 stars$8.88+3.3%$35.67+301.7%+57.7%$462.01MN/A-11.2410Short Interest ↑News CoverageIRONDisc Medicine2.6011 of 5 stars$58.54-1.2%$87.50+49.5%-6.2%$1.74BN/A-14.7130Short Interest ↑News CoverageWVEWave Life Sciences4.8316 of 5 stars$11.28-2.3%$22.22+97.0%+131.4%$1.72B$53.61M-10.16240BLTEBelite Bio3.2761 of 5 stars$55.00-0.8%$89.00+61.8%+22.6%$1.70BN/A-49.5510Short Interest ↓News CoveragePositive NewsGap DownARQTArcutis Biotherapeutics2.4588 of 5 stars$13.70-0.8%$16.60+21.2%+287.8%$1.60B$138.71M-7.65150Short Interest ↓Gap UpGLPGGalapagos1.6789 of 5 stars$24.31-5.2%$30.75+26.5%-37.2%$1.60B$260.09M0.001,123INDVIndivior2.0995 of 5 stars$11.56-2.4%$16.00+38.4%-24.1%$1.59B$1.18B-288.931,164Short Interest ↑News CoverageGap DownAKROAkero Therapeutics3.8331 of 5 stars$22.50-9.4%$46.83+108.1%+16.6%$1.57BN/A-6.0030Analyst ForecastNews CoverageDYNDyne Therapeutics3.5673 of 5 stars$15.16-4.5%$49.91+229.2%-12.8%$1.54BN/A-4.26100Analyst ForecastNews CoverageIMCRImmunocore2.5907 of 5 stars$29.90-1.6%$65.64+119.5%-58.2%$1.50B$296.31M-31.47497EVOEvotec2.262 of 5 stars$4.18-4.1%$5.93+41.9%-48.4%$1.48B$777.05M0.004,200Short Interest ↑ Related Companies and Tools Related Companies Disc Medicine Alternatives Wave Life Sciences Alternatives Belite Bio Alternatives Arcutis Biotherapeutics Alternatives Galapagos Alternatives Indivior Alternatives Akero Therapeutics Alternatives Dyne Therapeutics Alternatives Immunocore Alternatives Evotec Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GHRS) was last updated on 1/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GHRS Stock Alerts